Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus

D. A. Horbach, Erica van Oort, Richard C. J. M. Donders, +2

Thrombosis and Haemostasis

Complexes of anti‐prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces

Marleen J. A. Simmelink, D. A. Horbach, Ronald H. W. M. Derksen, +4

British Journal of Haematology

The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity--discrimination between functional and non-functional anti-prothrombin-antibodies.

D. A. Horbach, Erica van Oort, R. H. W. M. Derksen, +1

PubMed

ImmunologyPathologyImmunotherapyThrombosisLac Activity +17

The Contribution of Anti-prothrombin-antibodies to Lupus Anticoagulant Activity

Erica van Oort, Ronald H. W. M. Derksen, Philip de Groot, +1

Thrombosis and Haemostasis

ImmunohematologyImmunodeficienciesImmunologyPathologyLupus Anticoagulant Activity +17

Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis.

D. A. Horbach, Erica van Oort, Ton Lisman, +3

PubMed

Proteinlipid InteractionProtein SecretionGlycobiologyImmunologyThrombosis +17

Factor V Leiden, Antiphospholipid Antibodies and Thrombosis in Systemic Lupus Erythematosus

Rob Fijnheer, D. A. Horbach, R C J M Donders, +6

Thrombosis and Haemostasis

Vascular DiseaseVasculitisImmunologyPathologyAntiphospholipid Antibodies +17

β2-Glycoprotein I Is Proteolytically Cleaved In Vivo upon Activation of Fibrinolysis

Erica Oort, Ton Lisman, Joost C.M. Meijers, +3

Thrombosis and Haemostasis

Proteinlipid InteractionGlycobiologyMolecular BiologyMolecular PharmacologyProtein Expression +14

Transient monocular blindness and antiphospholipid antibodies in systemic lupus erythematosus

R C J M Donders, L. Jaap Kappelle, R. H. W. M. Derksen, +4

Neurology

The prevalence of a non-phospholipid-binding form of beta2-glycoprotein I in human plasma--consequences for the development of anti-beta2-glycoprotein I antibodies.

D. A. Horbach, Erica van Oort, Mariëlle J. Tempelman, +2

PubMed

ImmunologyPathologyHyperlipidemiaThrombosisHematology +19

Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: Relation to lipophilicity and membrane effects

Marcel J.E. Fischer, Jeannette J.C. Paulussen, D. A. Horbach, +4

Inflammation Research

Membrane EffectsAllergyMedicineLipid PeroxidationImmunology +8